Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Rheumatology (Oxford) ; 62(1): 341-346, 2022 12 23.
Article in English | MEDLINE | ID: mdl-35686919

ABSTRACT

OBJECTIVES: To describe the effectiveness and safety of biologics for the treatment of relapsing and/or refractory polyarteritis nodosa (PAN). METHODS: A retrospective European collaborative study was conducted in patients with PAN who received biologics for relapsing and/or refractory disease. RESULTS: Forty-two patients with PAN received a total of 53 biologic courses, including TNF-α blockers in 15 cases, rituximab (RTX) in 18 cases, tocilizumab (TCZ) in 10 cases and other biologics in 10 cases. TNF-α blockers and TCZ were mainly used for refractory diseases whereas RTX was mainly initiated for relapsing disease. After a median follow-up of 29 (8-50) months, remission, partial response, treatment failure and treatment discontinuation due to severe adverse events occurred in, respectively, 40%, 13%, 40% and 7% of patients receiving TNF-α blockers, 50%, none, 30% and 20% of TCZ recipients, and 33%, 11%, 56% and none of the RTX recipients. No remission was noted in patients treated with other biologics. Severe adverse events were observed in 14 (28%) patients without significant differences between the three biologics, leading to early biologics discontinuation in only three cases. CONCLUSION: These results suggest that TCZ may be effective in relapsing and/or refractory PAN. Our data warrant further study to confirm these findings.


Subject(s)
Antirheumatic Agents , Arthritis, Rheumatoid , Biological Products , Polyarteritis Nodosa , Humans , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Biological Products/therapeutic use , Immunologic Factors/therapeutic use , Polyarteritis Nodosa/drug therapy , Retrospective Studies , Rituximab/therapeutic use , Treatment Outcome , Tumor Necrosis Factor-alpha
2.
Arthritis Rheumatol ; 73(3): 498-503, 2021 03.
Article in English | MEDLINE | ID: mdl-33001543

ABSTRACT

OBJECTIVE: To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS: Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was 2 (IQR 1-5). In patients receiving RTX, the median BVAS declined both at 6 months (median 1, IQR 0-4.5) and at 12 months (median 0, IQR 0-2), and the frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 49%, 24%, 24%, and 3%, respectively. For the treatment of glucocorticoid (GC)-dependent asthma, patients who received MEPO had a much better GC-sparing effect and overall response than did patients who received OMA. The frequency of remission, partial response, treatment failure, and stopping treatment due to adverse events was 15%, 33%, 48%, and 4%, respectively, in the OMA group and 78%, 10%, 8%, and 4%, respectively, in the MEPO group. Remission rates at 12 months were 76% and 82% among patients receiving MEPO at a doses of 100 mg and 300 mg, respectively. CONCLUSION: These results suggest that RTX could be effective in treating relapses of EGPA vasculitis. MEPO is highly effective with a good safety profile in patients with GC-dependent asthma. Our data suggest that 100 mg MEPO monthly could be an acceptable dosage for first-line therapy in selected instances of EGPA, recognizing, however, that this has not been compared to the validated dosage of 300 mg monthly.


Subject(s)
Asthma/drug therapy , Biological Products/therapeutic use , Churg-Strauss Syndrome/drug therapy , Immunologic Factors/therapeutic use , Adult , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Asthma/physiopathology , Churg-Strauss Syndrome/physiopathology , Female , Glucocorticoids/therapeutic use , Humans , Male , Middle Aged , Omalizumab/therapeutic use , Recurrence , Retrospective Studies , Rituximab/therapeutic use , Treatment Failure , Treatment Outcome
3.
Presse Med ; 49(3): 104035, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32645417

ABSTRACT

Immunoglobulin A vasculitis (IgAV, formerly Henoch-Schönlein purpura) is a systemic inflammatory disease affecting small vessels. While it is common and usually benign in childhood, in adults it is rarer has a more severe course. Its main manifestations are cutaneous purpura, arthralgias or arthritis, acute enteritis and glomerulonephritis. Renal involvement is associated with a poor prognosis in adults. The treatment of adult-onset IgAV is still a matter of debate: although in patients with a non-severe phenotype remission can occur spontaneously, more severe cases may need immunosuppressive therapy. There are some areas of uncertainty with respect to the efficacy of immunosuppressive regimens: almost all data come from studies performed in children or from patients with IgA nephropathy and/or IgA-crescentic glomerulonephritis. The only randomised study performed in adults with IgAV and renal involvement showed that immunosuppressive therapy with cyclophosphamide did not improve renal outcome nor did it affect patient survival. The possible efficacy of other drugs is reported only in small case series. Recent evidences show that rituximab could be an effective therapeutic option for adult-onset IgAV, but this also needs to be confirmed in controlled trials. In this review, we focus on therapeutic options for adult-onset IgAV treatment, and discuss the main results of the studies performed so far.


Subject(s)
IgA Vasculitis/therapy , Therapies, Investigational/trends , Adult , Age of Onset , Cardiology/methods , Cardiology/trends , Child , Glomerulonephritis, IGA/drug therapy , Glomerulonephritis, IGA/pathology , Hematology/methods , Hematology/trends , Humans , IgA Vasculitis/epidemiology , IgA Vasculitis/pathology , Immunoglobulin A/adverse effects , Immunoglobulin A/immunology , Immunosuppressive Agents/therapeutic use , Rituximab/therapeutic use , Therapies, Investigational/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...